PRIVIGEN AU normal immunoglobulin (human) 40g (100g/L, 10%) solution for intravenous infusion Australia - englanti - Department of Health (Therapeutic Goods Administration)

privigen au normal immunoglobulin (human) 40g (100g/l, 10%) solution for intravenous infusion

csl behring australia pty ltd - normal immunoglobulin, quantity: 40 g - injection, solution - excipient ingredients: water for injections; proline - replacement therapy for primary immunodeficiency diseases (pid), myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections, symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulatory therapy for idiopathic thrombocytopenic purpura (itp) in patients at high risk of bleeding or prior to surgery to correct the platelet count, guillain-barr syndrome (gbs), kawasaki disease, chronic inflammatory demyelinating polyneuropathy (cidp), multifocal motor neuropathy (mmn), myasthenia gravis (mg) exacerbations, lambert-eaton myasthenic syndrome (lems), stiff person syndrome (sps).

PRIVIGEN AU normal immunoglobulin (human) 20g (100g/L, 10%) solution for intravenous infusion Australia - englanti - Department of Health (Therapeutic Goods Administration)

privigen au normal immunoglobulin (human) 20g (100g/l, 10%) solution for intravenous infusion

csl behring australia pty ltd - normal immunoglobulin, quantity: 20 g - injection, solution - excipient ingredients: water for injections; proline - replacement therapy for primary immunodeficiency diseases (pid), myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections, symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulatory therapy for idiopathic thrombocytopenic purpura (itp) in patients at high risk of bleeding or prior to surgery to correct the platelet count, guillain-barr syndrome (gbs), kawasaki disease, chronic inflammatory demyelinating polyneuropathy (cidp), multifocal motor neuropathy (mmn), myasthenia gravis (mg) exacerbations, lambert-eaton myasthenic syndrome (lems), stiff person syndrome (sps).

PRIVIGEN AU normal immunoglobulin (human) 10g (100g/L, 10%) solution for intravenous infusion Australia - englanti - Department of Health (Therapeutic Goods Administration)

privigen au normal immunoglobulin (human) 10g (100g/l, 10%) solution for intravenous infusion

csl behring australia pty ltd - normal immunoglobulin, quantity: 10 g - injection, solution - excipient ingredients: proline; water for injections - replacement therapy for primary immunodeficiency diseases (pid), myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections, symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulatory therapy for idiopathic thrombocytopenic purpura (itp) in patients at high risk of bleeding or prior to surgery to correct the platelet count, guillain-barr syndrome (gbs), kawasaki disease, chronic inflammatory demyelinating polyneuropathy (cidp), multifocal motor neuropathy (mmn), myasthenia gravis (mg) exacerbations, lambert-eaton myasthenic syndrome (lems), stiff person syndrome (sps).

PRIVIGEN AU normal immunoglobulin (human) 5g (100g/L, 10%) solution for intravenous infusion Australia - englanti - Department of Health (Therapeutic Goods Administration)

privigen au normal immunoglobulin (human) 5g (100g/l, 10%) solution for intravenous infusion

csl behring australia pty ltd - normal immunoglobulin, quantity: 5 g - injection, solution - excipient ingredients: proline; water for injections - replacement therapy for primary immunodeficiency diseases (pid), myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections, symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulatory therapy for idiopathic thrombocytopenic purpura (itp) in patients at high risk of bleeding or prior to surgery to correct the platelet count, guillain-barr syndrome (gbs), kawasaki disease, chronic inflammatory demyelinating polyneuropathy (cidp), multifocal motor neuropathy (mmn), myasthenia gravis (mg) exacerbations, lambert-eaton myasthenic syndrome (lems), stiff person syndrome (sps).

XEMBIFY normal immunoglobulin 10 g/50 mL (20%) solution for subcutaneous injection vial Australia - englanti - Department of Health (Therapeutic Goods Administration)

xembify normal immunoglobulin 10 g/50 ml (20%) solution for subcutaneous injection vial

grifols australia pty ltd - human immunoglobulin g, quantity: 9000 mg - solution - excipient ingredients: glycine; polysorbate 80; water for injections - indications for subcutaneous administration (scig),xembify? is indicated as replacement therapy in adult and paediatric patients for:,- primary immunodeficiency diseases (pid),- symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.

XEMBIFY normal immunoglobulin 1 g/5 mL (20%) solution for subcutaneous injection vial Australia - englanti - Department of Health (Therapeutic Goods Administration)

xembify normal immunoglobulin 1 g/5 ml (20%) solution for subcutaneous injection vial

grifols australia pty ltd - human immunoglobulin g, quantity: 900 mg - solution - excipient ingredients: glycine; polysorbate 80; water for injections - indications for subcutaneous administration (scig),xembify? is indicated as replacement therapy in adult and paediatric patients for:,- primary immunodeficiency diseases (pid),- symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.

XEMBIFY normal immunoglobulin 4 g/20 mL (20%) solution for subcutaneous injection vial Australia - englanti - Department of Health (Therapeutic Goods Administration)

xembify normal immunoglobulin 4 g/20 ml (20%) solution for subcutaneous injection vial

grifols australia pty ltd - human immunoglobulin g, quantity: 3600 mg - solution - excipient ingredients: glycine; polysorbate 80; water for injections - indications for subcutaneous administration (scig),xembify? is indicated as replacement therapy in adult and paediatric patients for:,- primary immunodeficiency diseases (pid),- symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.

XEMBIFY normal immunoglobulin 2 g/10 mL (20%) solution for subcutaneous injection vial Australia - englanti - Department of Health (Therapeutic Goods Administration)

xembify normal immunoglobulin 2 g/10 ml (20%) solution for subcutaneous injection vial

grifols australia pty ltd - human immunoglobulin g, quantity: 1800 mg - solution - excipient ingredients: glycine; polysorbate 80; water for injections - indications for subcutaneous administration (scig),xembify? is indicated as replacement therapy in adult and paediatric patients for:,- primary immunodeficiency diseases (pid),- symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.

Water for Injections Freeflex Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

water for injections freeflex

fresenius kabi new zealand limited - water for injection 100% - solution for injection - active: water for injection 100% - water for injections is used to dissolve or dilute substances or preparations for parenteral administration. water for injections may also be used as an irrigating solution for small wounds or during minor surgical procedures.

Water for Injections BP Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

water for injections bp

fresenius kabi new zealand limited - water for injection 100%{vol} - solution for injection - active: water for injection 100%{vol} - water for injection bp is used to dissolve or dilute substances or preparations for parenteral administration. water for injection bp may also be used as an irrigating solution for small wounds or during minor surgical procedures.